MoonLake Reports Third-Quarter 2026 Financial Results and Business Update
MoonLake said it submitted a Biologics License Application for sonelokimab to the U.S. Food and Drug Administration.
Story updates
12:15:12 PM UTC
SquawkNews
MoonLake reported a net loss of $79.5 million for the third quarter of 2026 and ended September with $498.5 million in cash, cash equivalents and short-term marketable debt securities. Research and development expenses rose to $68.9 million, primarily reflecting accrued license milestone fees relat…